Verrica Pharmaceuticals Operating Expenses Growth & History (VRCA)
Verrica Pharmaceuticals's operating expenses was $47.8M for fiscal 2025.
View full Verrica Pharmaceuticals company overviewVerrica Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $47.8M | −$25.7M | −35.00% |
| 2024 | 2024-12-31 | $73.5M | $2.6M | +3.67% |
| 2023 | 2023-12-31 | $70.9M | $40.6M | +133.72% |
| 2022 | 2022-12-31 | $30.3M | −$12.6M | −29.32% |
| 2021 | 2021-12-31 | $42.9M | $2.7M | +6.79% |
| 2020 | 2020-12-31 | $40.2M | $10.1M | +33.58% |
| 2019 | 2019-12-31 | $30.1M | $8.2M | +37.49% |
| 2018 | 2018-12-31 | $21.9M | $17.4M | +390.87% |
| 2017 | 2017-12-31 | $4.5M | — | — |
Verrica Pharmaceuticals quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $19.0M | $7.8M | +69.40% |
| Q1 2026 | 2026-03-31 | $14.7M | $3.2M | +27.39% |
| Q4 2025 | 2025-12-31 | $12.3M | $530,000 | +4.51% |
| Q3 2025 | 2025-09-30 | $12.7M | −$6.2M | −32.80% |
| Q2 2025 | 2025-06-30 | $11.2M | −$9.2M | −45.09% |
| Q1 2025 | 2025-03-31 | $11.6M | −$10.9M | −48.41% |
| Q4 2024 | 2024-12-31 | $11.8M | — | — |
| Q3 2024 | 2024-09-30 | $18.9M | −$7.9M | −29.48% |
| Q2 2024 | 2024-06-30 | $20.4M | $8.6M | +72.77% |
| Q1 2024 | 2024-03-31 | $22.4M | $15.3M | +214.69% |
| Q3 2023 | 2023-09-30 | $26.8M | $20.0M | +290.54% |
| Q2 2023 · Jun 30 | 2023-06-30 | $11.8M | $2.5M | +26.38% |
| Q1 2023 | 2023-03-31 | $7.1M | −$715,000 | −9.12% |
| Q4 2022 | 2022-12-31 | $6.3M | −$2.2M | −25.84% |
| Q3 2022 | 2022-09-30 | $6.9M | −$4.9M | −41.61% |
| Q2 2022 | 2022-06-30 | $9.3M | −$1.4M | −13.01% |
| Q1 2022 | 2022-03-31 | $7.8M | −$4.1M | −34.33% |
| Q4 2021 | 2021-12-31 | $8.5M | −$3.6M | −29.62% |
| Q3 2021 | 2021-09-30 | $11.8M | $2.1M | +22.11% |
| Q2 2021 | 2021-06-30 | $10.7M | $2.1M | +24.33% |
| Q1 2021 | 2021-03-31 | $11.9M | $2.1M | +20.85% |
| Q4 2020 | 2020-12-31 | $12.0M | $4.0M | +50.60% |
| Q3 2020 | 2020-09-30 | $9.6M | $3.1M | +47.29% |
| Q2 2020 | 2020-06-30 | $8.6M | $1.1M | +14.76% |
| Q1 2020 | 2020-03-31 | $9.9M | $1.9M | +23.10% |
| Q4 2019 | 2019-12-31 | $8.0M | −$198,000 | −2.42% |
| Q3 2019 | 2019-09-30 | $6.5M | $211,000 | +3.33% |
| Q2 2019 | 2019-06-30 | $7.5M | $2.1M | +37.50% |
| Q1 2019 | 2019-03-31 | $8.0M | $6.1M | +325.11% |
| Q4 2018 | 2018-12-31 | $8.2M | $6.8M | +470.99% |
| Q3 2018 | 2018-09-30 | $6.3M | $5.0M | +366.27% |
| Q2 2018 | 2018-06-30 | $5.5M | $4.4M | +399.54% |
| Q1 2018 | 2018-03-31 | $1.9M | $1.3M | +231.23% |
| Q4 2017 | 2017-12-31 | $1.4M | — | — |
| Q3 2017 | 2017-09-30 | $1.4M | — | — |
| Q2 2017 | 2017-06-30 | $1.1M | — | — |
| Q1 2017 | 2017-03-31 | $570,000 | — | — |
Verrica Pharmaceuticals operating expenses trends
Over the last five fiscal years, Verrica Pharmaceuticals's operating expenses increased from $40.2M to $47.8M, a change of $7.6M. The latest reported quarter, Q2 2026, shows $19.0M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Verrica Pharmaceuticals source filings ↗